Hepatitis B virus (HBV) infection is the most prevalent chronic viral infection and about two billion people have been infected with this virus worldwide (1). According to the World Health Organization (WHO) estimates, 257 million individuals (3.5%) of the world’s population lived with chronic HBV infection worldwide in 2015. Moreover, 887 thousand deaths occur annually because of HBV, often because of its long-term complications, including cirrhosis and hepatocellular carcinoma. Furthermore, about half of deaths from liver cancer has been associated with HBV infection (2). The widespread use of hepatitis B vaccine has significantly reduced the incidence rate of new chronic HBV infection among infants, so that since the start of the global vaccination program (which varies from 1980s to the early 2000s) until 2015, the ratio of children under the age of 5 who were chronically affected by this virus has fallen from 4.7% to 1.3%, and most of individuals currently living with HBV infection are those who have been born prior to the start of the national vaccination program (2). By the end of 2011, vaccination against HBV infection in children’s routine vaccination programs has been implemented in 180 countries (3). In various studies, the effective response to the vaccine (based of the definition, individuals with HBS-Ab of more than 10 miu/ml) has been achieved among almost 95% of healthy individuals, with a preservation and durability of more than 15 years (4-6). In Iran, hepatitis B vaccination program has been routinely executed among infants since 1993 (7).

Background

Hepatitis B virus (HBV) infection is the most prevalent chronic viral infection and about two billion people have been infected with this virus worldwide (1). According to the World Health Organization (WHO) estimates, 257 million individuals (3.5%) of the world's population lived with chronic HBV infection worldwide in 2015. Moreover, 887 thousand deaths occur annually because of HBV, often because of its long-term complications, including cirrhosis and hepatocellular carcinoma. Furthermore, about half of deaths from liver cancer has been associated with HBV infection (2). The widespread use of hepatitis B vaccine has significantly reduced the incidence rate of new chronic HBV infection among infants, so that since the start of the global vaccination program (which varies from 1980s to the early 2000s) until 2015, the ratio of children under the age of 5 who were chronically affected by this virus has fallen from 4.7% to 1.3%, and most of individuals currently living with HBV infection are those who have been born prior to the start of the national vaccination program (2). By the end of 2011, vaccination against HBV infection in children's routine vaccination programs has been implemented in 180 countries (3). In various studies, the effective response to the vaccine (based of the definition, individuals with HBS-Ab of more than 10 miu/ml) has been achieved among almost 95% of healthy individuals, with a preservation and durability of more than 15 years (4-6). In Iran, hepatitis B vaccination program has been routinely executed among infants since 1993 (7). Moreover, this vaccine is

Hepatitis B Vaccination Coverage, HBS-Ab Level and its Related Factors among Dentistry and Medical Students

Sajjad Shamloo1, Parivash Davoodian2, Koorosh Nematpour2*, Mehdi Hassani Azad2, Habib Dadvand2

1Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Abstract
Background: In Iran, hepatitis B vaccination has been routinely performed for infants since 1993. This vaccination has also been suggested for individuals at risk. Recently, with the birth of children in 1993 and later to the age of entry to the university, assuming they were vaccinated against hepatitis B at birth, the issue of tracking the immunity of these students has been obscured or neglected. Moreover, the entry of some individuals born before 1993 to the university who have not been immunized against this disease in childhood, has made this issue more complicated.

Objectives: The aim of this study was to investigate Hepatitis B Vaccination Coverage, HBS-Ab level and its related factors among dentistry and medical students.

Methods: This study was a cross-sectional study performed through providing a checklist and serological tests. After obtaining written consent from the students, the information of 300 students were entered into SPSS software, version 16.0, and analyzed using descriptive statistics. Kruskal-Wallis and Mann-Whitney U tests were used and P<0.05 was considered as statistically significant.

Results: Of the 300 students, 55%, 28.7%, and 16.3% had weak, medium, and good HBS-Ab titer with rates of less than 10, 10 to 100, and more than 100, respectively, moreover, the mean HBS-Ab titer was significantly different between different immune groups (Weak, Medium, and Good) (P<0.000) (Write P<0.001 instead of P<0.000). Vaccination coverage was at a very low level so that only 6.3% of the subjects completed the hepatitis B vaccination in the past 1 to 5 years (when entering university), the mean HBS-Ab titer was significantly correlated with the time elapsed since the last vaccination (P<0.05) (It was better to write the exact P values). The immunity level among the married individuals and clinical students was significantly higher compared to the single individuals and preclinical students, respectively (P<0.05).

Conclusions: Considering the low level of vaccination coverage among the students of Hormozgan University of Medical Sciences (6.3%) compared with other universities, it is better to design a program that will allow all students enrolled in such fields to receive hepatitis B vaccination when entering the university.

Keywords: HBS-Ab titer, Vaccination coverage, Hepatitis B
recommended for individuals at risk such as dental and medical students. However, the vaccination of students has not been followed up seriously and is not mandatory for them. In the past, students born before 1993 (as the high-risk group), were routinely introduced to health centers to receive a hepatitis vaccine and were vaccinated when entering the university. In recent years, with the birth of individuals in 1993 and later to the age of entry to the university, assuming they were vaccinated against hepatitis B at birth, the issue of tracking the immunity of these student groups has been obscured or neglected. Given the current situation, the entry of some individuals born before 1993 to the university who have not been immunized against this disease in childhood, has made this issue more complex. Therefore, we decided to examine hepatitis B vaccination coverage, HBS-Ab level and its related factors among dentistry and medical students.

Methods

Study design and setting

This study was an observational cross-sectional and descriptive-analytic study conducted by providing a checklist and serological tests. This study was done on the students of dental and medical schools of Hormozgan University of Medical Sciences during the fall and winter seasons of 2017.

Study participants and sampling

Based on the information obtained from the Deputy Education of Hormozgan University of Medical Sciences, the total number of dental and medical students of this university was 1200. Using the Cochran formula with 95% confidence level and 5% error rate, as well as considering the incidence rate of the disease in previous studies (50%) (8), the required sample size was calculated to be 291 individuals, and by considering the possible drop-out rate, 320 individuals were considered for the study. The sampling was performed using multi-stage cluster method. All dental and medical students who were completely willing to participate were enrolled regardless of their history of vaccination.

Data collection, variables, and measurements

After obtaining written consent from the students, 5cc blood sample was taken from them. To determine the antibody level against HBV, all the samples were evaluated for HBS-Ab level by enzyme-linked immunosorbent assay (ELISA) and using anti-HBs Pishatzeb kit in the laboratory of Shahid Mohammadi Hospital affiliated to Hormozgan University of Medical Sciences. HBS-Ab levels below 10 mIU/mL were considered as weak, and HBS-Ab levels of 10-100 and more than 100 mIU/mL indicated medium and good immunity levels, respectively. After collecting checklists, some of them were excluded from the study because of numerous drawbacks. Ultimately, the information of 300 individuals were entered into the SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA). The checklist for each individual included demographic information and questions about the variables. In all stages of the research, their information was considered and remained confidential.

Data analysis

Data were analyzed by SPSS software, version 16. Initially, Kolmogorov-Simonov test was used to examine the normal distribution of HBS-Ab titer variable, and it was found that the data had an abnormal distribution, then they were evaluated using descriptive statistics such as mean and standard deviation (SD) of quantitative variables and percentage rate of qualitative variables, and Kruskal-Wallis H and Mann-Whitney U tests. Moreover, \( P<0.05 \) was considered as statistically significant.

Results

This study was performed on 300 students of dental and medical students of Hormozgan University of Medical Sciences during the fall and winter seasons of 2017. The study population consisted of people born during 1980-1999. 44 of them were born before 1993 and 256 were born after 1993. This is important for us because people born after 1993 have participated in the national neonatal vaccination plan. 173 (57.7%) and 127 (42.3%) of the participants were men and women, respectively. 165 (55%), 86 (28.7%), and 49 (16.3%) of the subjects had weak, medium, and good level of HBS-Ab titer with rates of less than 10, 10, to 100 mIU/mL, and more than 100 mIU/mL, respectively (Figure 1). The mean HBS-Ab titers were significantly different in different immune groups (weak, medium, and good) \( (P=0.000) \).

Vaccination coverage was at a very low level so that only 6.3% of the participants completed the hepatitis B vaccination in the past 1 to 5 years (when entering university, Table 1). The mean HBS-Ab titer had a significant relationship with the time elapsed since the last vaccination, so that the mean HBS-Ab titer among individuals with the last vaccination in the past 1 to 5 years was significantly higher compared with individuals

![Figure 1. Immunity level of students in percent](hmj.hums.ac.ir)
who had their last vaccination in the past 5 to 25 years (Figure 2). The mean value of HBS-Ab titers among the individuals born before the launch of the vaccination program was significantly higher among those born after the start of this program ($P<0.05$). In other words, the mean of HBS-Ab titers was higher among older people.

The immunity level of the married individuals was significantly higher compared with the single ones (effect size $[ES]=-0.405$, $P=0.046$). Moreover, the immunity level in women was higher than that of men ($ES=0.137$, $P=0.347$), of course this relationship was not significant.

The immunity level of individuals studying in clinics was significantly higher than the ones studying in preclinical stage ($P=0.049$, $ES=0.231$). Furthermore, the immunity level among the dentistry students was significantly higher than the mean titer in medical students ($P=0.003$, $ES=0.239$, Table 2).

The level of immunity did not show a significant relationship with the variables of body mass index (BMI), family income, exercise, smoking, alcohol use, and type of blood group ($P>0.05$).

**Discussion**

The results of this study revealed that more than half of the dental and medical students studied (55%) had poor antibody titers (HBS-Ab<10), most of whom being those who had received the vaccine only at birth and the rest being individuals with no record of vaccinations at all. As mentioned, a portion of the study population was individuals who were not included in the national vaccination program. From this group, a number of individuals had received three doses of HBV (complete vaccination) spontaneously or by their university and the others had not received hepatitis B vaccine at all (without vaccination). The mean value of HBS-Ab titers among the individuals born before the launch of the vaccination program was significantly higher among those born after the start of this program. Since these individuals have not received the hepatitis B vaccine at birth, they may have received the vaccine for example in high school, during the military service, or during the previous university degrees spontaneously or from the relevant health centers.

Vaccination is the main procedure of preventing HBV. However, issues such as the number of vaccines needed, the appropriate age for receiving these doses, the need or lack of need for booster doses, etc., have been the place of disagreement. Moreover, the effectiveness of the hepatitis B vaccine has varied in various studies taking into account the time elapsed since the last dose of vaccine, the age of receiving the vaccine, the population studied, the residence place, and the incidence rate of hepatitis B. Table 3 demonstrates the effectiveness of hepatitis B vaccination in various studies.

As shown, in all studies, the effectiveness of vaccination against HBV drops over time, and the high rate of vaccination effectiveness in some of the studies can be attributed to the circumstances of performing the study including the population studied, the incidence of HBV in the region, the lifestyle of individuals, the age of receiving vaccine doses, the number of doses of vaccination, the time past from the last dose of vaccination, and even the year of conducting the study. In the present study, the immunity level was significantly reduced over time. However, as seen in this figure, a relative increase can be observed.
observed in the mean HBS-Ab titer among individuals without a history of vaccination; this increase in the HBS-Ab titer can be attributed to a variety of reasons, such as the respondents’ error regarding receiving or not receiving a vaccine or the remaining high rate of HBS-Ab titer because of having a history of HBV infection.

Given the reduction of HBS-Ab protection titer over time, it has been suggested that individuals with risky occupations receive booster dose or doses to increase their immunity, and since dental and medical students

| Table 2. Relationship between type of field and educational level with immunity level |
|-----------------|------------------|-----------------|-----------------|-----------------|
| Field           | Section          | HBS-Ab groups   | Total           |
|                 |                  | Weak | Medium | Good |                    |
| Dentistry       | Preclinic        | 25   | 17     | 5    | 47                |
|                 | % within section | 53.2%| 36.2%  | 10.6%| 100.0%            |
|                 | % within HBS-Ab groups | 30.9%| 37.0%  | 12.2%| 28.0%             |
|                 | Count            | 56   | 29     | 36   | 121               |
|                 | Dentistry Clinic | 46.3%| 24.0%  | 29.8%| 100.0%            |
|                 | % within section | 69.1%| 63.0%  | 87.8%| 72.0%             |
|                 | % within HBS-Ab groups | 383.3%| 92.5%  | 87.5%| 86.4%             |
|                 | Count            | 81   | 46     | 41   | 168               |
| Medical         | Preclinic        | 48.2%| 27.4%  | 24.4%| 100.0%            |
|                 | % within section | 100.0%| 100.0% | 100.0%| 100.0%            |
|                 | % within HBS-Ab groups | 70   | 37     | 7    | 114               |
|                 | Count            | 14   | 3      | 1    | 18                |
| Medical         | Clinic           | 77.8%| 16.7%  | 5.6% | 100.0%            |
|                 | % within section | 16.7%| 7.5%   | 12.5%| 13.6%             |
|                 | % within HBS-Ab groups | 84   | 40     | 8    | 132               |
|                 | Count            | 84   | 40     | 8    | 132               |

| Table 3. Effectiveness of hepatitis B vaccination on rising the HBS-Ab titer in various studies |
|----------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Efficacy of vaccination (HBS-Ab≥10) | Years past from vaccination | N of Vaccination doses | country | Number of participants | Vaccinated population | Year of publication | Reference |
|--------------------------------|---------------------------|------------------------|---------|----------------------|-----------------------|----------------------|-----------|
| 51.72%                       | 10                        | 3-4doses Starting at birth | UK     | 116                  | Infants of carrier mothers | 2004 | (9)            |
| 91.2%                       | 11                        | 3doses                  | Italy   | 228                  | Adolescents           | 2007 | (10)          |
| 64% infants and 89%recruits  | 10                        | 3doses                  | Italy   | 1212 infants and 446recruits | Infants and recruits | 2005 | (11)          |
| 37.8%                       | 15-21                     | 3doses Starting at birth | Taiwan  | 6156                 | Infants               | 2008 | (12)          |
| 50%                         | 20                        | 3doses Starting at birth | Iran    | 441                  | Infants               | 2014 | (8)           |
| 60%                         | 22                        | 3doses                  | Alaska native | 493    | Age>6month           | 2009 | (5)           |
| 56%                         | 22                        | 3doses                  | Alaska native | 71     | Age=6month-4year     | 2009 | (5)           |
| 81.1%-81.8%                 | 15                        | 2-3doses                | Czech Republic and Belgium | 162     | Age=12-15 years      | 2016 | (13)          |
| 51.44%                      | 30                        | 3doses                  | Alaska native | 243    | Age>6month           | 2016 | (14)          |
| 77%                         | 21                        | 3doses Starting at birth | Italy   | 588                  | Infants               | 2015 | (15)          |
| 93.5%                       | 14                        | 3doses Starting at birth | Iran (Isfahan) | 200    | Infants               | 2012 | (16)          |
| 71%                         | 10-15                     | 3doses Starting at birth | Iran (Semnan) | 76     | Infants               | 2014 | (17)          |
are directly at risk of transmitting infections to patients through different ways, it is suggested that the immunity of these individuals be specially considered (17-19). Table 4 illustrates the manner of vaccination of medical students in different European countries (20).

In this study, it was observed that Hormozgan Medical University lacked a suitable monitoring of hepatitis B vaccination and it was only offered to students just as a suggestion. Definitely, this is one of the most important reasons for the low vaccination coverage among the students (only 6.3%). However, this rate is much better in other studies. In Nigeria, Solofa and colleagues and Okeke and colleagues reported vaccination coverage of 47.7% and 37.9% for medical students and dental students, respectively. Similarly, Al-Dabbas reported a 76.8% coverage of vaccination for medical students (21, 22). Moreover, since the past several years, in universities such as the Frankfurt University of Medical Sciences, Germany, which has approximately 2,730 and 4,200 medical students and employees, respectively, there is a plan for the free vaccination for all health care workers and the first checkup of the medical students is done in the second year of study, before dealing with a patient (23).

In the present study, the immune system response to vaccination was better in women compared to men, however there was no significant relationship. This was consistent with the result of another study (24). However, in other studies (25, 26), immune responses to vaccination in women were significantly higher compared with men. The most important causes for the differences in studies include cases such as the age range of the subjects, the time of the first vaccination, the regional incidence of hepatitis, the sensitivity of the measuring kits, etc. In most studies, immune response was better in men than women, however the reason for this issue is still unclear.

In the current study, there was a significant relationship between the level of immunity against HBV (weak, medium and good) and marital status, but in most other studies (27, 28), there was no specific relationship between these two variables, and the reason for the significant relationship in this study may be attributed to the low number of married individuals.

In this study, vaccination and hence, the mean HBS-Ab titer among clinical students was higher than that of pre-clinical students; this finding was similar to those reported in the studies by Sabine Wicker, Kesieme, Okeke and their colleagues (22, 23, 29). Of course, as shown in table 3, this higher HBS-Ab titer was true in dental individuals of clinical students, and this is somehow inverse in medicine, which may be related to the fact that the number of individuals selected from medical clinics is much lower than the medical preclinical students. This lower number of selected clinical medical students has caused the mean HBS-Ab titer among dentistry students to be significantly higher than medical students (P = 0.003, ES = 0.239). One of the most important reasons for the low level of vaccination in pre-clinical students can be the lack of information on the importance of vaccination, ignorance of the risk of HBV, the lack of communication with the patient in preclinical period, and so on. However, contact with HBV increases in preclinical years, so, it is better to perform vaccination among students of these fields when entering the university. For instance, in one study (30) conducted at Nigerian medical universities, 21.7% of the people exposed accidentally to blood were individuals who were studying in the preclinical course. In the present study, similar to other studies (14, 24, 31), there was no significant correlation between mean HBS-Ab titer with variables such as BMI, smoking, and type of blood group.

One of the constraints of this study was the lack of proportion to the size rule for selection of dental and medical students, as well as the assumption that all individuals who were born in 1993 and later received neonatal vaccination completely.

| country          | Medical students | Nurses students | Paramedical students | Included in universal adolescent/infant programs |
|------------------|------------------|-----------------|----------------------|-----------------------------------------------|
| Austria          | R                | R               | R                    | Yes                                           |
| Belgium          | M                | M               | M                    | Yes                                           |
| Czech Republic   | M                | M               | M                    | No information                                |
| Denmark          | N                | N               | N                    | Yes                                           |
| France           | M                | M               | M                    | Yes                                           |
| Germany          | R                | R               | R                    | Yes                                           |
| Ireland          | R                | R               | R                    | Yes                                           |
| Italy            | R                | R               | R                    | Yes                                           |
| Poland           | M                | M               | M                    | Yes                                           |
| UK               | R                | R               | R                    | No information                                |
| Spain            | R                | R               | R                    | Yes                                           |

M, mandatory; R, recommended; N, neither mandatory nor recommended.

Table 4. Recommendations for hepatitis B vaccination for different categories of student healthcare workers in European countries (20).
Conclusion

Since 55% of the students had a level of antibodies lower than the protective level (HBS-Ab< 10), Hormozgan University of Medical Sciences should conduct an HBS-Ab test for all dental and medical students and then perform one or more vaccine booster doses. Also, because of the low level of vaccination coverage among students in Hormozgan University of Medical Sciences (6.3%) compared to other universities, it is better to design a program based on which all students enrolled in the university receive hepatitis B vaccination upon enterance.

Informed Consent

Not applicable

Competing interests

The authors declare that they have no competing interests

Funding

This study was conducted with the support and financial aid of the Infectious-Tropical Diseases Research Center of Hormozgan University of Medical Sciences.

Authors’ contributions

Study conception and design: PD, KN, HD. Data collection: KN, SSH. Data analysis and interpretation: KN, PD. Critical discussion and manuscript revision: PD, KN, SSH, HD, MHA. All authors read and approved the final manuscript.

Acknowledgments

The researchers would like to thank Dr. Pedram Ansari, head of the Department of Dentistry of Hormozgan University of Medical Sciences who helped us with the idea and design of this study.

References

1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053-63. doi: 10.1016/s0140-6736(14)60220-8.

2. World Health Organization (WHO). Global Hepatitis Report 2017. WHO; 2017.

3. World Health Organization (WHO). Hepatitis B fact sheet 2014. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/index.html, 2015.

4. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine. 2013;31(4):584-90. doi: 10.1016/j.vaccine.2012.10.101.

5. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-6. doi: 10.1086/606119.

6. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013;8(3):e58029. doi: 10.1371/journal.pone.0058029.

7. Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI): a systematic review and meta-analysis study. Hepat Mon. 2015;15(5):e23618. doi: 10.5812/pehmon.15(04)2015.23618.

8. Nooshiravanpour P, Ramazenkhan A, Gashani M, Khodakarim S, Hatami H. Immunity against hepatitis-B among freshman students at Shahid Beheshti University of Medical Sciences, academic year 2012-2013. Research in Medicine. 2014;38(3):176-80. [Persian].

9. Boxall EH, J AS, El-Shuikri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190(7):1264-9. doi: 10.1086/423818.

10. Gabbuti A, Romano L, Blanc P, Meacci F, Amendola A, Mele A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007;25(16):3129-32. doi: 10.1016/j.vaccine.2007.01.045.

11. Zanetti AR, Mariano A, Romano L, D’Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379-84. doi: 10.1016/s0140-6736(05)67568-x.

12. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26. doi: 10.1086/587695.

13. Beran J, Van Der Meeren O, Leyssen M, D’Silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine. 2016;34(24):2686-91. doi: 10.1016/j.vaccine.2016.04.033.

14. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16-22. doi: 10.1093/infdis/jiv748.

15. Coppola N, Corvino AR, De Pascalis S, Signoriello G, Di Fiore E, Nienhaus A, et al. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC Infect Dis. 2015;15:149. doi: 10.1186/s12879-015-0874-3.

16. Taghavi Ardakani A, Soltani B, Sharif MR, Moosavi G, Khademian M. Evaluation of serum hepatitis B antibody level in vaccinated children after 14 years in Kashan, Iran. J Gorgan Univ Med Sci. 2012;14(3):104-8. [Persian].

17. Rezaei M, Nooripoor S, Ghorbani R, Ramezanshams F, Mamishi S, Mahmoudi S. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. J Prev Med Hyg. 2014;55(1):1-3.

18. Weber DJ, Rutala WA. Vaccines for Health Care Personnel.: 6th ed. Elsevier Inc; 2012.

19. De Schryver A, Claesen B, Meheus A, van Sprundel M, François G. European survey of hepatitis B vaccination policies for healthcare workers. Eur J Public Health. 2011;21(3):338-43. doi: 10.1093/eurpub/cqk122.

20. De Schryver A, Claesen B, Meheus A, Hambach R, van Sprundel M, François G. Hepatitis B vaccination policies
21. Sofola OO, Folayan MO, Denloye OO, Okeigbemen SA. Occupational exposure to bloodborne pathogens and management of exposure incidents in Nigerian dental schools. J Dent Educ. 2007;71(6):832-7.

22. Okeke EN, Ladep NG, Agaba EI, Malu AO. Hepatitis B vaccination status and needle stick injuries among medical students in a Nigerian university. Niger J Med. 2008;17(3):330-2. doi: 10.4314/njm.v17i3.37404.

23. Wicker S, Rabenau HF, von Gierke L, François G, Hambach R, De Schryver A. Hepatitis B and influenza vaccines: important occupational vaccines differently perceived among medical students. Vaccine. 2013;31(44):5111-7. doi: 10.1016/j.vaccine.2013.08.070.

24. Nashibi R, Alavi SM, Yousefi F, Salmanzadeh S, Moogahi S, Ahmadi F, et al. Post-vaccination immunity against hepatitis B virus and predictors for non-responders among medical staff. Jundishapur J Microbiol. 2015;8(3):e19579. doi: 10.5812/jjm.19579.

25. Khodaveisi M, Mohammadi N, Omidi A, Amini R. Antibody titers of hepatitis B in Hamadan’s nursing and midwifery students. Avicenna J Nurs Midwifery Care. 2010;18(1):45-55. [Persian].

26. Mansour-Ghanaei F, Falah MS, Jafarshad R, Joukar F, Arami M, Ale-Esmaili A, et al. The Immunologic Response to anti-hepatitis B vaccination among medical students of Guilan University of Medical Sciences, Guilan, Iran. Hepat Mon. 2006;6(2):63-6.

27. Ghorbani GA, Alavian SM, Ghadimi HR. Long term effects of one or two doses of hepatitis B vaccine in adults after five years. Pak J Biol Sci. 2008;11(4):660-3. doi: 10.3923/pjbs.2008.660.663.

28. Ghorbani GA, Alavian SM, Esfahani AA. Long-term protection of hepatitis B vaccine in adult. J Med Sci. 2007;7(7):1214-7.

29. Kesieme EB, Uwakwe K, Irekpita E, Dongo A, Bwala KJ, Alegbeleye BJ. Knowledge of hepatitis B vaccine among operating room personnel in Nigeria and their vaccination status. Hepat Res Treat. 2011;2011:157089. doi: 10.1155/2011/157089.

30. Noubiap JJ, Nansseu JR, Kengne KK, Tchokfe Ndoula S, Agyingi LA. Occupational exposure to blood, hepatitis B vaccine knowledge and uptake among medical students in Cameroon. BMC Med Educ. 2013;13:148. doi: 10.1186/1472-6920-13-148.

31. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010;51(5):1547-54. doi: 10.1002/hep.23543.